113 related articles for article (PubMed ID: 11715881)
1. [Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
MMW Fortschr Med; 2001 Oct; 143(43):50. PubMed ID: 11715881
[No Abstract] [Full Text] [Related]
2. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
[No Abstract] [Full Text] [Related]
3. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
4. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
5. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
7. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
8. [Losartan and the kidney protection. The RENAAL study].
Recenti Prog Med; 2001 Dec; 92(12):788. PubMed ID: 11822103
[No Abstract] [Full Text] [Related]
9. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Tershakovec AM; Keane WF; Zhang Z; Lyle PA; Appel GB; McGill JB; Parving HH; Cooper ME; Shahinfar S; Brenner BM
Diabetes Care; 2008 Mar; 31(3):445-7. PubMed ID: 18070995
[TBL] [Abstract][Full Text] [Related]
10. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
11. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
13. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
Nilsson P; Attvall S
Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
[No Abstract] [Full Text] [Related]
14. Achieved vs initial blood pressure in predicting renal outcomes.
Onuigbo MA
Arch Intern Med; 2004 Jan; 164(2):223; author reply 223-4. PubMed ID: 14744850
[No Abstract] [Full Text] [Related]
15. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
[TBL] [Abstract][Full Text] [Related]
16. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Agha A; Amer W; Anwar E; Bashir K
Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
[TBL] [Abstract][Full Text] [Related]
17. Best practice for hypertensive patients with kidney disease.
de Zeeuw D
Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337
[TBL] [Abstract][Full Text] [Related]
18. The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes.
Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S162-94. PubMed ID: 20591029
[No Abstract] [Full Text] [Related]
19. [Diabetic nephropathy].
Körner A
Orv Hetil; 1985 Jul; 126(28):1701-5. PubMed ID: 3936000
[No Abstract] [Full Text] [Related]
20. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
Abuissa H; O'Keefe J
Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
